The estimated Net Worth of James L Vincent is at least $10.8 Million dollars as of 15 June 2010. James Vincent owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $10,476,400 and over the last 19 years James sold ALNY stock worth over $336,141.
James has made over 3 trades of the Alnylam Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently James sold 22,100 units of ALNY stock worth $336,141 on 17 June 2010.
The largest trade James's ever made was exercising 32,900 units of Alnylam Pharmaceuticals Inc stock on 11 June 2010 worth over $230,958. On average, James trades about 9,444 units every 1 days since 2005. As of 15 June 2010 James still owns at least 40,000 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of James Vincent stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: